Details
Ciprinol INDICATIONS:
Adults - Uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens: respiratory tract infection. While outpatient treatment of pneumonia caused by pneumococcus, ciprofloxacin should not be used as a drug of first choice.
Ciprofloxacin is recommended for the treatment of pneumonia caused by Klebsiella spp, Enterobacter spp, Proteus spp, Escherichia coli, Pseudomonas aeruginosa, Haemophilus spp, Moraxella catarrhalis, Legionella, and staphylococci....;
middle ear infections (otitis media) and paranasal sinuses (sinusitis), especially infections caused by gram-negative microorganisms, especially Pseudomonas aeruginosa, staphylococci, or; eye infection; abdominal infections, bacterial gastrointestinal infections, gallbladder and biliary tract, as well as peritonitis;
kidney and urinary tract infections; pelvic infection (gonorrhea, adnexitis, prostatitis);
Skin and soft tissue infections; infections of bones and joints; sepsis;
prevention and treatment of infections in immunocompromised patients (including in the treatment of neutropenia and immunosuppressants);
selective decontamination of the intestine during treatment with immunosuppressants;
prevention of invasive disease caused by Neisseria meningitides; reducing the risk of occurrence or progression of anthrax after aerogenic contact with Bacillus anthracis.
Children
Ciprofloxacin can be used in children as a second or third drug for the treatment of a number of complicated urinary tract infections and pyelonephritis caused by E. coli (clinical trials in children age treated amounted to 1 year or 17 years), as well as for the treatment of respiratory disease exacerbations system caused by Pseudomonas aeruginosa, in children with cystic fibrosis lung (in clinical studies age children receiving treatment was 5-17 years).
Treatment with ciprofloxacin may be imposed only after careful assessment of risk / benefit ratio in view of the likelihood of side effects from the joints and / or surrounding tissue.
Cildren treatment in clinical trials carried out only for the above indications.
Clinical experience with the use of ciprofloxacin in children for other indications is limited.
Adults and children - reducing the risk of occurrence or progression of anthrax after aerogenic contact with Bacillus anthracis.
